EyePoint, Inc. develops and commercializes therapeutics for serious retinal diseases as a clinical-stage biopharmaceutical company. Its lead product candidate, DURAVYU (vorolanib intravitreal insert), is an investigational sustained-delivery treatment that uses bioerodible Durasert E technology and is being studied for wet age-related macular degeneration and diabetic macular edema.
Recurring EyePoint news covers clinical program updates, financial results, FDA naming and product-status disclosures, manufacturing and commercial-readiness topics, investor presentations, and equity inducement grants under Nasdaq Listing Rule 5635(c)(4). Company updates also address cash resources, corporate development activity, and disclosures tied to its Nasdaq-listed common stock.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
EyePoint Pharmaceuticals (NASDAQ: EYPT) has announced a conference call and live webcast set for May 3, 2023, at 8:30 a.m. ET to report its first-quarter 2023 financial results and discuss recent corporate developments. The event will provide investors an opportunity to gain insights into the company's performance and strategic initiatives. EyePoint is focused on developing therapeutics for serious eye disorders, leveraging its proprietary Durasert technology for sustained drug delivery. Among its pipeline products is EYP-1901, currently in Phase 2 clinical trials, which targets intravitreal anti-VEGF treatment. EyePoint’s products, including YUTIQ, have previously gained FDA approval, showcasing its commitment to advancing eye care solutions.
EyePoint Pharmaceuticals (NASDAQ: EYPT) announced on April 17, 2023, the grant of non-statutory stock options for 13,000 shares to two new employees as part of an inducement package outside its 2016 Long-Term Incentive Plan. The options were granted on April 14, 2023, with an exercise price set at $4.33 per share, reflecting the stock’s closing price on that date. The options have a ten-year term and vest over four years, beginning with 25% vesting after one year, followed by monthly vesting thereafter. This move is in accordance with NASDAQ Listing Rule 5635(c)(4) and aims to enhance recruitment efforts by offering competitive compensation packages to new talent.